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Background: Fractional exhaled nitric oxide (FENO) has been implicated as a pulmonary
biomarker. The aim of this study was to compare the performance of a new hand-held device
to a standard chemiluminescence analyzer and to another portable device.
Methods: FENO levels measured by NObreath (Bedfont) were compared to those of (1) a chemi-
luminescence detector (Logan, Logan Research) and (2) the electrochemical portable NIOX
MINO (Aerocrine) in 18 healthy volunteers on three consecutive occasions: in the morning,
1 h and 24 h later.
Results: Comparing FENO levels obtained by NObreath to those by Logan values were similar
and a very close linear relationship was found between the two devices (r Z 0.923,
p < 0.001). The mean inter-device difference in FENO level was 3.45 ppb and the limits of
agreement (BlandeAltman test) were 10.98 and 4.08 ppb. In the second series FENO levels
obtained by NObreath were found to be slightly higher compared to those of NIOX MINO,
but still showed a close correlation (r Z 0.681, p < 0.001). The mean inter-device difference
in FENO level was 4.36 ppb and the limits of agreement were 7.38 and 16.1 ppb. Analyzing
the repeated FENO measurements, the mean coefficient of variation using NObreath tended
to be lower than that of NIOX MINO (16.9 vs. 24.7%, p Z 0.059), while it was similar as the
value obtained with Logan (11.8 vs. 9.0%, p Z 0.342).
Conclusions: FENO values measured with NObreath are reproducible and in good agreement
with those obtained by NIOX MINO and Logan indicating that NObreath is suitable for use in
clinical practice.
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Measurement of fractional exhaled nitric oxide (FENO) is
a simple and completely non-invasive method for assessing
airway inflammation.1 FENO has been implicated as
a pulmonary biomarker in various respiratory diseases,
particularly bronchial asthma.2e5
Chemiluminescence-based analysis is considered to be
the gold standard technique for measuring FENO. Chem-
iluminescence analyzers are fast-responding, highly sensi-
tive and specific for nitric oxide gas. However, several
factors such as size, cost and frequent calibration limit
their permeation into routine clinical practice.
To overcome these limitations electrochemical sensors
suitable for FENO detection in exhaled breath have recently
been developed, and incorporated into hand-held
measuring devices. The first such portable device was the
NIOX MINO (Aerocrine AB, Solna, Sweden).6 This instrument
has been tested and was shown to provide values in good
agreement with those obtained by the standard chem-
iluminescence analyzer.7e11
More recently, a new hand-held device (NObreath;
Bedfont Scientific Ltd., Rochester, Kent, UK) has been
developed. The aim of this study was to compare the
performance of the NObreath device with a standard,
stationary chemiluminescence analyzer and the NIOX MINO.
Materials and methods
Study subjects
Thirty-six non-smoking healthy volunteers (16 men, 20
women, mean age: 46.6  3.1 years) were enrolled into the
study. Subjects had normal lung function values with no
history of atopy, acute or chronic respiratory diseases in the
previous four weeks. The research protocol was approved
by the local Ethics Committee, and all subjects gave
written informed consent to participate in the study.
Study design
Participants were divided into two groups (n Z 18 for each
group). In the first group FENO levels were measured by
NObreath in parallel with Logan (study 1) and in the secondTable 1 FENO levels (ppb) obtained by different devices at the
Logan NObreath
Study 1
T1 13.0 (10.1e16.7) 15.7 (11.7e
T2 13.5 (10.4e17.4) 14.8 (10.4e
T3 12.9 (9.9e16.6) 16.4 (12.3e
Study 2
T1 e 14.9 (11.9e
T2 e 16.1 (13.3e
T3 e 16.3 (12.8e
Data are presented as geometric mean with 95% CI.
a Logan vs. NObreath.
b NObreath vs. NIOX MINO, ppb: parts per billion.with NIOX MINO (study 2) at three consecutive occasions: in
the morning at 09:00 h (T1), 1 h (T2) and 24 h later (T3).
In study 1 measurements at each occasion were performed
in triplicate and the mean value was used in the calcula-
tions. In study 2 only one measurement per device was
performed at each occasion. Measurements were per-
formed in randomized device order.
Measurements of fractional exhaled nitric oxide
FENO levels were recorded using either a chem-
iluminescence analyzer (Logan LR2500, Logan Research
Ltd., Rochester, UK), the NIOX MINO or the NObreath at an
exhalation flow rate of 50 mL/s.12,13 For NObreath, subjects
first inhaled ambient air to near total lung capacity and
then exhaled for 16 s at a constant flow rate through
a mouthpiece into the device. The instrument has a color
touch screen with visual prompts for subjects whilst taking
the test. As a visual feedback, an eye level flow indicator (a
small bullet in a plastic tube) helped the subjects keeping
a constant flow during exhalation.
Statistical analysis
Data are presented as mean  SEM or geometric mean with
95% CI when appropriate. For comparison between devices
correlation coefficients were estimated and BlandeAltman
plots were constructed. As FENO concentrations exhibited
a non-normal distribution (KolmogoroveSmirnov test),
correlation coefficients were calculated by the Spearman
method. Comparison between FENO levels of different
devices was performed by the Mann Whitney test. The
reproducibility of FENO readings was assesses by the coef-
ficient of variation (CV) and the BlandeAltman test. All
calculations were performed using GraphPad Prism 4.0
(GraphPad Software Inc., San Diego, CA, USA) software
package. A p value <0.05 was considered significant.
Results
Study 1
In study 1 subject presented a FENO range of 3e49 ppb.
Mean FENO levels (derived from triplicate measurements)three assessment points.
NIOX MINO p value
21.9) e 0.299a
21.3) e 0.351a
21.9) e 0.179a
18.8) 12.6 (9.3e17.1) 0.409b
19.6) 10.3 (7.8e13.4) 0.010b
20.6) 10.9 (8.4e14.2) 0.043b
Figure 1 Correlation of fractional exhaled nitric oxide (FENO) readings between (a) NObreath and Logan and (b) NObreath and
NIOX MINO (measurements at three time-points are presented in each graph). In panel (a) each point on the graph represents the
mean value of three measurements, while in panel (b) each point corresponds to one measurement.
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linear relationship was found between the values obtained
by the two devices at each assessment point (T1: rZ 0.897,
p < 0.001; T2: r Z 0.913, p < 0.001; T3: r Z 0.938,
p < 0.001). Fig. 1a shows the correlation of FENO readings
between the two devices.
The BlandeAltman plot showed a high degree of agree-
ment between the two devices: the mean intrasubject
difference in FENO level was 3.95 ppb and the limits of
agreement were 10.98 and 4.08 ppb (Fig. 2a).
The mean CV of repeated FENO readings were similar
(NObreath: 11.8 vs. Logan: 9.0%, p Z 0.342). The limits of
agreement for repeated FENO measurements were 4.6
and 5.0 for NObreath and 3.0 and 3.3 ppb for Logan,
respectively.
Study 2
In study 2 subjects presented a FENO range of 3e36 ppb.
FENO readings by NObreath were higher compared to those
of NIOX MINO; however, this only reached significance at
assessment points T2 and T3 (Table 1). The mean difference
in FENO level was 4.2 ppb. There was a close correlation
between FENO levels measured by the two devices at each
time-point (T1: r Z 0.662, p Z 0.004; T2: r Z 0.750,Figure 2 Agreement between (a) NObreath and Logan and (b) N
comparing the inter-device mean to the inter-device difference (me
In panel (a) each point on the graph represents the mean value of th
one measurement.p < 0.001; T3: r Z 0.654, p Z 0.003). Fig. 1b shows the
correlation of FENO readings between the two devices.
Comparing the two devices, the mean intrasubject
difference in FENO readings was 4.36 ppb (Fig. 2b). On the
BlandeAltman plot the limits of agreement were 7.38 and
16.1 ppb.
The mean CV of repeated FENO readings using NObreath
was lower compared to that of NIOX MINO; however, this
difference was not significant (16.9 vs. 24.7%, p Z 0.059).
The limits of agreement for repeated FENO measurements
were 8.2 and 6.5 for NObreath and 8.2 and 13.2 ppb for
NIOX MINO, respectively.
Discussion
NObreath is new, portable, easy-to-use device with an
electrochemical sensor similar to that of NIOX MINO, the
other currently available hand-held device. Most of the
technical parameters of the two instruments are similar.
In this study Logan and NObreath yielded similar FENO
readings at each time-point. By contrast, FENO readings by
NObreath were slightly higher (by approximately 4 ppb) than
those of NIOX MINO at two of the three assessment points.
Nevertheless, there was a close correlation between FENO
values obtained by the devices in both parts of our study.Obreath and NIOX MINO as reflected by the BlandeAltman plot
asurements at three time-points are presented in each graph).
ree measurements, while in panel (b) each point corresponds to
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the BlandeAltman method to determine the limits of
agreement. Using NObreath we found that the mean CV
tended to be lower and the limits of agreement were
somewhat larger compared to NIOX MINO indicating that the
reproducibility of FENO measurements with NObreath is
slightly better. The CV for NIOX MINO was similar to previ-
ously reported values of our14 and other groups.10 By
employing triplicate measurements at each assessment
point in the first series, the mean CV of FENO readings by
NObreath decreased from 16.9 to 11.8% and the limits of
agreement for repeated measurements by NObreath also
narrowed (8.2 and 6.5 vs. 4.6 and 5.0). This finding is
reasonable and indicates that the reproducibility of FENO
measurements with NObreath can be improved with three
parallel readings. Nevertheless, even when performing
triplicate measurements, the reproducibility of FENO read-
ings with Logan as assessed by the CV (9%) and the limits of
agreement (3.0 and 3.3 ppb) was still better compared to
NObreath. Nonetheless, the difference was minor and from
a clinical point of view we believe that this is negligible.
We are aware that our findings on healthy subjects
cannot be automatically extrapolated to higher FENO
ranges found typically in asthmatics. Nevertheless, FENO
levels in our study were in a wide range, and from a clinical
point of view, device accuracy is more important in a FENO
range close to the cut-off between health and disease
(20e35) ppb than at higher FENO level. Finally, it is also
possible that differences in FENO readings between
NObreath and NIOX MINO may be augmented or minimized
when FENO is measured in asthmatics.
In conclusion, FENO levels measured by a new portable
device, the NObreath are reliable, reproducible and show
a good agreement with those obtained by previously vali-
dated instruments. Our results indicate that NObreath is
suitable for use in clinical practice.Acknowledgements
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